Delayed Reactions After Allergy Shots: What You Need to Know

Yes, though true systemic allergic reactions the following day are uncommon. The documented delayed reaction window extends from 30 minutes to approximately 6 hours for most delayed systemic events (Greenberg 1986, JACI). However, biphasic anaphylaxis — a recurrence of anaphylaxis after apparent resolution — can occur up to 72 hours after the initial event, most commonly at 4 to 10 hours. Additionally, late-phase local swelling at the injection site commonly peaks 24 to 48 hours after injection and can cause noticeable discomfort the next day. What patients often experience as a 'next-day reaction' is typically either late-phase local swelling, post-injection fatigue and malaise from cytokine release, or occasionally a mild delayed systemic reaction. Any next-day symptom beyond the injection arm warrants a call to your allergist.

According to the AAAAI/ACAAI National Surveillance Study (Epstein 2011), approximately 15% of all systemic reactions to allergy shots begin after the 30-minute clinic observation window. This figure has been reproduced in a 2019 update covering 54.4 million injection visits. The breakdown by grade: 15% of Grade 1 reactions, 10% of Grade 2 reactions, and 12.5% of Grade 3 reactions were delayed in onset. A single-center 10-year analysis (Larenas-Linnemann 2017) reported a higher proportion — 52.8% — suggesting that the 15% figure may underestimate delayed reaction frequency in some clinical settings. The bottom line: delayed reactions are real, not rare, and patients should remain alert for new symptoms in the hours after each injection, particularly during build-up and after new vial transitions.

Delayed reactions to allergy shots have several distinct mechanisms depending on the type. Delayed systemic reactions involve the same IgE-mediated mast cell pathway as immediate reactions, but with slower allergen absorption and mediator release — often related to injection site depth, body temperature, or physical activity after the shot. Late-phase local swelling is a distinct process driven by eosinophil, basophil, and T-cell recruitment to the injection site, beginning 6 to 12 hours after injection and peaking at 24 to 48 hours. Biphasic anaphylaxis likely results from secondary mast cell degranulation triggered by residual allergen or persistent IgE cross-linking. Risk factors documented in the AAAAI/ACAAI Practice Parameter include beta-blocker use, concurrent pollen season exposure, new vial transitions, and a prior history of systemic reactions.

Several factors increase the risk of delayed reactions after allergy shots. Beta-blocker medications impair the epinephrine response and may potentiate mast cell mediator release, making reactions both more likely and harder to treat. Dose escalation periods carry higher reaction rates than stable maintenance dosing. New vial transitions — even at the same nominal concentration — can produce potency variation that increases reaction risk. Peak pollen season is a well-documented risk modifier: the AAAAI/ACAAI Year 3 surveillance (Epstein 2013) found practices that reduced doses during peak season had significantly fewer Grade 2 and 3 reactions. A prior history of any systemic reaction is associated with a fourfold higher rate of subsequent systemic reactions (Roy 2007, Ann Allergy). Uncontrolled asthma is the single most important risk factor for severe reactions overall.

Post-injection fatigue is commonly reported by allergy shot patients, especially during the build-up phase or after dose escalations, and it is mechanistically plausible. Allergen exposure during SCIT triggers transient cytokine release — including IL-1, IL-6, and TNF-alpha from late-phase immune cells — which are well-established mediators of fatigue and what immunologists call 'sickness behavior.' The same pathway is responsible for the tiredness people feel during infections or after vaccines. However, this side effect is not systematically quantified in the AAAAI/ACAAI surveillance data — it is an acknowledged evidence gap. Typically, fatigue lasts hours to about 24 hours and is more prominent during build-up. Fatigue lasting more than 48 hours, or accompanied by hives, wheezing, fever, or throat tightness, warrants a call to your allergist.

The decision depends on the nature and severity of the delayed symptoms. A mild delayed reaction — hives beyond the injection site, increased sneezing, or abdominal cramping — warrants calling your allergist immediately rather than defaulting to the ER. However, any symptom suggesting anaphylaxis — throat tightening, difficulty breathing, audible wheezing, dizziness, or lightheadedness — requires immediate action: use your prescribed epinephrine auto-injector, call 911, and go to the emergency room. This is especially critical if you already experienced a reaction during your clinic visit, because biphasic anaphylaxis can recur 1 to 72 hours after the first event resolves. AAAAI Anaphylaxis Practice Parameters recommend 4 to 8 hours of observation after moderate anaphylaxis and up to 24 hours after severe reactions — which means ER care, not watchful waiting at home.

Post-injection fatigue that lasts hours to about one day is commonly reported and is thought to reflect late-phase immune activation — specifically the cytokine signaling (IL-1, IL-6, TNF-alpha) that accompanies the secondary cellular response to allergen exposure. It is more common during dose build-up phases and after escalations. Most allergists and AAAAI patient education materials acknowledge it as a recognized, though poorly quantified, side effect. However, fatigue alone — without accompanying symptoms such as hives, wheezing, throat tightness, or fever — is unlikely to represent a clinically significant delayed systemic reaction. If fatigue is severe, persists beyond 48 hours, or appears with other symptoms, contact your allergist to rule out a low-grade systemic delayed reaction or other cause.